SCHEMBL707610

SCHEMBL707610

CC(=O)Nc1ccc(C=Cc2cnc3ccccc3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.62
KDM4E B2RXH2 4/20 0.62
RAB9A P51151 9/20 0.57
NPC1 O15118 8/20 0.57
KMT2A Q03164 7/20 0.57
MEN1 O00255 6/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
HTT P42858 1/20 0.56
HSP90AA1 P07900 1/20 0.54
HSP90AB1 P08238 1/20 0.54
ATIC P31939 1/20 0.53
PABPC1 P11940 1/20 0.50
TP53 P04637 1/20 0.50
STAT1 P42224 1/20 0.50
MAPK1 P28482 1/20 0.49
POLB P06746 3/20 0.48
MCL1 Q07820 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PAX8 Q06710 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707609 1.00 MAPT (0.62) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL9784094 0.83 MAPT (0.51) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL21974449 0.82 PAX8 (0.52) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL12923109 0.81 PAX8 (0.63) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL22009097 0.79 TUBB4A (0.68) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL707640 0.79 RAB9A (0.54) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL707639 0.79 RAB9A (0.54) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL709375 0.78 RAB9A (0.52) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL709374 0.78 RAB9A (0.52) MAPTKDM4ERAB9ANPC1KMT2A
SCHEMBL712709 0.77 RAB9A (0.64) MAPTKDM4ERAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB MAPT 3896/4885KDM4E 4415/4885RAB9A 4723/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 MAPT 3909/4885KDM4E 4647/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.